Patient Characteristics (Intention-to-Treat Population)
| Characteristic | All patients (n = 190) | 18F-PSMA-1007 first (n = 102) | 18F-fluorocholine first (n = 88) |
|---|---|---|---|
| Median age (y)* | 69 (49–84) | 68 (49–81) | 70 (51–84) |
| Initial ISUP group grade at PCa diagnosis† | |||
| 1 | 29 (15.3) | 12 (11.8) | 17 (19.3) |
| 2 | 64 (33.7) | 32 (31.4) | 32 (36.4) |
| 3 | 55 (29.0) | 33 (32.4) | 22 (25) |
| 4 | 14 (7.4) | 8 (7.8) | 6 (6.8) |
| 5 | 21 (11.1) | 13 (12.8) | 8 (9.1) |
| Unknown | 7 (3.7) | 4 (3.9) | 3 (3.4) |
| Prior prostatectomy† | 154 (81) | 80 (78) | 74 (84) |
| With pelvic lymph node dissection (no. of patients) | 93 | 51 | 42 |
| Serum PSA levels, in ng/mL, before first PET examination‡ | |||
| Overall | 1.7 (0.6–4.2) | 2.0 (0.9–5.5) | 1.3 (0.6–3.1) |
| In patients with prior prostatectomy | 1.3 (0.5–3.2) | 1.7 (0.6–3.5) | 0.9 (0.4–2.5) |
| In patients without prior prostatectomy | 4.5 (2.3–9.9) | 6.3 (2.8–10.9) | 3.0 (2.1–9.0) |
| Serum PSA doubling time, in mo, before first PET examination‡ | 6.3 (3–12.1) | 6.4 (3.0–11.6) | 5.9 (2.7–12.6) |
| PSA doubling time ≤ 6 mo (% of patients) | 49 | 47 | 51 |
| PSA doubling time ≤ 12 mo (% of patients) | 74 | 76 | 70 |